Researchers use ovarian follicles to preserve fertility
Technique could be beneficial for women with cancer; study in mice produced live births
From: U-M Comprehensive Cancer Center News
Media contact: Nicole Fawcett, 734-764-2220 | Patients may contact Cancer AnswerLine™, 800-865-1125
ANN ARBOR, Mich. — Researchers at the University of Michigan have identified a potential new approach to fertility preservation for young cancer patients that addresses concerns about beginning cancer treatment immediately and the possibility of reintroducing cancer cells during the fertility preservation process.
The work, done in mice, has potential to expand options for girls and women undergoing cancer treatments that may impact their future fertility.
The researchers isolated primary ovarian follicles, consisting of the oocyte and surrounding cells. They encapsulated the follicles in a gel and then reimplanted them in mice. All mice transplanted with the follicles resumed normal ovarian cycles. One-third produced live births.
For many young women diagnosed with cancer, concerns about fertility rank high and may influence their decisions about cancer treatment. Current fertility preservation options for women include embryo or egg freezing, performed using hormonal stimulation to induce ovulation. Hormonal stimulation is not possible for all young patients. Some are too young and some cannot afford to delay cancer treatment.
“This research is an important advance in the potential expansion of fertility preservation options for young patients who may not be able to undergo hormone stimulation to induce ovulation before beginning chemotherapy,” says study author Jacqueline S. Jeruss, M.D., Ph.D., associate professor of surgery and director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center.
“This study also provides new information on a method to reduce or eliminate cancer cell exposure during the fertility preservation process,” she adds.
Fear of reintroducing cancer
Researchers are also studying ovarian tissue transplantation for patients with cancer. A key concern with this approach is the risk that the ovarian tissue may harbor latent cancer cells that, upon transplantation, could be reintroduced back into the patient. Cancer cells are known to circulate throughout the body even in early stage invasive disease.
In this new study, when researchers isolated the follicles, they substantially reduced the presence of cancer cells. Two of the five tested transplanted materials had no residual cancer cells.
“The success rate for traditional in vitro fertilization is approximately 33 percent per cycle. For cancer patients, the oocytes or embryos that are cryo-preserved before cancer treatment may become their entire reproductive future,” says study author Lonnie D. Shea, Ph.D., William and Valerie Hall Chair and professor of biomedical engineering at the University of Michigan.
“The ovary can have tens to hundreds of thousands of follicles. If we can access that pool to preserve fertility, we could potentially create many more chances for reproductive success for these patients,” Shea adds.
Refining the technique
The authors tested three types of biomaterial for preserving the follicles. They hope that by refining their study techniques they can produce even better results. Additional research is also needed to ensure that all cancer cells are consistently eliminated from the follicles every time this tissue is transplanted.
As the work’s promise continues, the researchers envision that ovarian follicles could be extracted and preserved till the woman was ready to pursue pregnancy. At that point, the follicles would be matured and then fertilized. More research is needed before this technique can be tested in humans.
“Fertility is an important part of survivorship for young cancer patients,” Jeruss says. “It’s crucial to identify new techniques to make more fertility preservation options available for women and girls being treated for cancer.”
The study is published in the Nature journal Scientific Reports.
Note to patients: This work was done in mice and is not currently available for use in humans. Call the Cancer AnswerLine at 800-865-1125 to speak to a nurse about available fertility preservation options.
Additional authors: Ekaterina Kniazeva and Teresa K. Woodruff, from Northwestern University; A.N. Hardy from Fox Chase Cancer Center; Samir Boukaidi, from Centre Hospitalier Universitaire de Nice
Funding: National Institutes of Health grant U54 HD076188
Disclosure: None
Reference: Scientific Reports, “Primordial Follicle Transplantation within Designer Biomaterial Grafts Produce Live Births in a Mouse Infertility Model,” published online Dec. 3, 2015,doi:10.1038/srep17709